Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB

Ian Frazer

Anixa Biosciences (NASDAQ:ANIX) appointed cancer vaccine pioneer, Dr. Ian Frazer, to its scientific advisory board. 

Dr. Frazer is a leading immunologist recognized as one of the first scientists to study the link between immunity to human papillomavirus (HPV) infection and cervical cancer. His research began more than 25 years ago when he and his colleague, the late Jian Zhou, co-invented a technology for virus-like particles that trigger an immune response against HPV. 

Their breakthrough became the basis of two approved cancer vaccines, Gardasil and Cervarix. The two vaccines are highly effective in protecting against HPV associated infection, which are known to be the cause of cervical and other cancers. 

“With his unique knowledge of vaccine technology, Dr. Frazer joins us at an opportune time, as we have expanded our therapeutic portfolio with a prophylactic cancer vaccine that has the potential to eliminate certain types of breast cancer,” Amit Kumar, president and CEO, said in a statement.